Axon Enterprise (NASDAQ:AXON) Stock Price Target Cut by Needham & Company LLC

Axon Enterprise (NASDAQ:AXON) had its price objective decreased by analysts at Needham & Company LLC from $750.00 to $500.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC‘s target price would indicate a potential upside of 30.70% from the company’s current price.

Several other equities research analysts have also recently weighed in on the company. Morgan Stanley upped their target price on Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Royal Bank Of Canada restated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, July 21st. Barclays lifted their price objective on Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Northcoast Research upped their price objective on shares of Axon Enterprise from $650.00 to $680.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $672.75.

Axon Enterprise Stock Down 9.8%

Shares of NASDAQ AXON opened at $382.56 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. The firm has a market capitalization of $31.08 billion, a price-to-earnings ratio of 158.74, a PEG ratio of 8.06 and a beta of 1.48. The stock has a 50 day moving average price of $447.49 and a 200 day moving average price of $476.73. Axon Enterprise has a 52-week low of $339.01 and a 52-week high of $665.07.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Friday, November 6th. The biotechnology company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.89 by ($0.17). The firm had revenue of $908.55 million during the quarter, compared to the consensus estimate of $934.33 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%. The firm’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same period last year, the company earned $1.17 EPS. Sell-side analysts expect that Axon Enterprise will post 2.10 earnings per share for the current year.

Insider Activity

In other Axon Enterprise news, President Joshua Isner sold 16,775 shares of Axon Enterprise stock in a transaction on Monday, August 31st. The shares were sold at an average price of $574.43, for a total value of $9,636,063.25. Following the transaction, the president directly owned 296,974 shares of the company’s stock, valued at approximately $170,590,774.82. The trade was a 5.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Isaiah Fields sold 1,017 shares of the company’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $480.45, for a total value of $488,617.65. Following the transaction, the insider directly owned 56,264 shares in the company, valued at approximately $27,032,038.80. The trade was a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 37,397 shares of company stock worth $21,234,034. 4.20% of the stock is currently owned by insiders.

Institutional Trading of Axon Enterprise

Institutional investors have recently made changes to their positions in the business. Keel Point LLC increased its stake in shares of Axon Enterprise by 4.4% in the 1st quarter. Keel Point LLC now owns 599 shares of the biotechnology company’s stock valued at $254,000 after purchasing an additional 25 shares in the last quarter. Bridgewater Advisors Inc. raised its holdings in Axon Enterprise by 4.4% in the 2nd quarter. Bridgewater Advisors Inc. now owns 616 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 26 shares during the period. Pinnacle Wealth Planning Services Inc. boosted its position in Axon Enterprise by 7.8% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 361 shares of the biotechnology company’s stock worth $153,000 after purchasing an additional 26 shares in the last quarter. Roman Butler Fullerton & Co. boosted its position in Axon Enterprise by 2.4% during the first quarter. Roman Butler Fullerton & Co. now owns 1,278 shares of the biotechnology company’s stock worth $500,000 after purchasing an additional 30 shares in the last quarter. Finally, 44 Wealth Management LLC boosted its position in Axon Enterprise by 6.0% during the first quarter. 44 Wealth Management LLC now owns 530 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 30 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon reported record Q3 revenue of $909 million, up 28% year over year. Drone-as-First-Responder revenue grew 43%, Platform Solutions revenue rose 106%, and AI annual recurring revenue surpassed $100 million. Net income was $57 million, versus a loss a year earlier, while adjusted EBITDA increased 33%. Read More.
• Neutral Sentiment: Axon committed an additional $1.2 billion to Skydio, bringing its stake to 37%, and became Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move strengthens Axon’s drone strategy, but the large investment also raises questions about capital allocation and the time needed for returns. Read More.
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million missed analyst estimates of $1.89 and roughly $934 million, respectively. Although revenue grew year over year, the miss is a concern for a high-growth, premium-valued stock. Read More.
• Negative Sentiment: The outlook was weaker than expected: Axon forecast Q4 revenue of $990 million–$1 billion versus consensus near $1.1 billion, and FY 2026 revenue of $3.6 billion versus about $3.7 billion. Reports also cite delays in federal drone business as a factor behind investor concerns. Read More.
• Negative Sentiment: Axon faces a class-action lawsuit over its AI-powered license-plate surveillance network, adding legal and reputational risk. Read More.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and connected products for public safety organizations. The company’s portfolio includes TASER conducted-energy weapons, body-worn cameras, in-car cameras, and related hardware designed to support law enforcement, corrections, security, and other emergency-response professionals.

Axon also provides cloud-based software for managing digital evidence, records, workflows, real-time operations, investigations, and communications. Its platform is intended to connect hardware, software, and services across the public-safety ecosystem, helping agencies collect, store, analyze, and share operational information.

The company was founded in 1993 as TASER International by Rick Smith and Tom Smith and adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into a broader technology platform.